一句话亮点

EGFR突变肺癌对奥希替尼的耐药，靠的是“踩下RRM2刹车、同时启动RRM2B备用引擎”这套双轨调控，维持dNTP供给；打断这条代谢代偿通路，耐药进程就能被明显拖慢。

背景/痛点

奥希替尼是EGFR突变非小细胞肺癌的三代TKI，初始响应很好，但耐药几乎都会出现。已知的耐药机制主要是二次突变、旁路激活这些“老面孔”。但这篇研究问了个不一样的问题：药物压制EGFR信号后，细胞代谢层面发生了什么？这些代谢调整会不会反过来帮细胞活下来？

dNTP是DNA复制和修复的原料，主要由核糖核苷酸还原酶（RNR）合成。RNR的催化大亚基是RRM1，小亚基有两个：RRM2在S期提供大部分dNTP，RRM2B在应激状态下被诱导出来“救场”。癌细胞增殖快，对dNTP供给高度依赖。如果EGFR抑制影响了dNTP生成，细胞能不能启动备用方案？备用方案又是怎么启动的？这就是本文的出发点。

推理链分步拆解

第一步：奥希替尼到底对转录组干了什么？

他们先用RNA-seq扫了一遍PC-9细胞（EGFR突变）在奥希替尼处理后的转录组变化。结果很明显：DNA复制、细胞周期、核苷酸代谢相关通路被显著抑制。其中RRM2和MYBL2是下降最明显的基因之一。

WB验证发现RRM2蛋白确实大幅下降，而且是EGFR突变细胞特异的——EGFR野生型的A549细胞没有这种变化。这说明RRM2下调不是药物脱靶效应，而是突变EGFR信号被切断后的直接后果。

那RRM2下降对dNTP池有什么影响？他们直接测了四种dNTP的含量，发现dCTP和dTTP这两类嘧啶核苷酸明显下降，而嘌呤类dATP/dGTP变化不大。这种选择性缺失，和RRM2主要负责嘧啶合成的功能是一致的。

@方法论点评：RNA-seq做全局筛选找到候选靶点，再用WB和dNTP定量做因果验证——先“发现”再“锁定”，逻辑严密。嘧啶特异性下降也与RRM2的功能吻合，这是“表型-机制”匹配的关键证据。

那RRM2下降是不是真的影响药物敏感性？他们过表达RRM2后做克隆形成实验，发现细胞对奥希替尼的耐受能力明显增强——RRM2水平本身就能决定细胞对药物的响应强度。

Fig. 1：Osi suppresses RRM2 expression and reduces dNTP levels in PC-9 and HCC827 cells. A, Volcano plot showing gene expression changes in PC-9 cells after treatment with Osi. The x-axis denotes fold expression change, and the y-axis shows the P value of the change. Genes with a log2 fold ex- pression change ≥1 and an adjusted P < 0.05 are highlighted. B, KEGG pathway enrichment analysis of genes downregulated by Osi in PC-9 cells. Pathways are ranked based on \x01log10 (P value). C, PC-9 and HCC827 cells were treated with the indicated con- centrations of Osi for 24 hours. Protein expression of RRM1 and RRM2 was assessed by WB, with GAPDH as a loading control. Results shown are representative of three independent experiments. D, Intracellular dNTP levels in PC-9 and HCC827 cells were quantified with or without 24-hour Osi treatment. Data are presented as mean ± SD from three independent biological replicates. E, PC-9 and HCC827 cells were transfected with FLAG-RRM2 for 48 hours. Protein ex- pression of FLAG and RRM2 was assessed by WB, with actin as a loading control. Results shown are representative of three independent experiments. F, Representative colony formation images of PC-9 and HCC827 cells were transfected with vector control or FLAG-RRM2 and treated with increasing concentrations of Osi. G, Quantification of colony density from F, illustrating the impact of RRM2 overexpression on cellular resistance to Osi. O/E, overexpression; NC, negative control.

Fig. 1. Osi suppresses RRM2 expression and reduces dNTP levels in PC-9 and HCC827 cells. A, Volcano plot showing gene expression changes in PC-9 cells after treatment with Osi. The x-axis denotes fold expression change, and the y-axis shows the P value of the change. Genes with a log2 fold ex- pression change ≥1 and an adjusted P < 0.05 are highlighted. B, KEGG pathway enrichment analysis of genes downregulated by Osi in PC-9 cells. Pathways are ranked based on log10 (P value). C, PC-9 and HCC827 cells were treated with the indicated con- centrations of Osi for 24 hours. Protein expression of RRM1 and RRM2 was assessed by WB, with GAPDH as a loading control. Results shown are representative of three independent experiments. D, Intracellular dNTP levels in PC-9 and HCC827 cells were quantified with or without 24-hour Osi treatment. Data are presented as mean ± SD from three independent biological replicates. E, PC-9 and HCC827 cells were transfected with FLAG-RRM2 for 48 hours. Protein ex- pression of FLAG and RRM2 was assessed by WB, with actin as a loading control. Results shown are representative of three independent experiments. F, Representative colony formation images of PC-9 and HCC827 cells were transfected with vector control or FLAG-RRM2 and treated with increasing concentrations of Osi. G, Quantification of colony density from F, illustrating the impact of RRM2 overexpression on cellular resistance to Osi. O/E, overexpression; NC, negative control.（图注取自PDF文本层，来源：Cancer Research, 2026）

第二步：MYBL2是怎么夹在EGFR和RRM2之间的？

那问题来了：EGFR信号是怎么调控RRM2转录的？RNA-seq里MYBL2同样被压制，而MYBL2已知能结合RRM2启动子。他们用ChIP-qPCR证明：MYBL2确实能招募RNA聚合酶II到RRM2启动子，促进转录；而且EGFR敲低会减少MYBL2在启动子上的结合。

更有意思的是，奥希替尼处理会降低MYBL2的酪氨酸磷酸化水平——这说明EGFR不仅调控MYBL2的表达量，还影响它的激活状态。这也就解释了为什么奥希替尼对RRM2的抑制如此高效。

@方法论点评：这里用了“三明治”式的因果关系验证——敲低EGFR、敲低MYBL2、抑制EGFR磷酸化，三路并进分别证明同一个结论。这种多重正交验证是区分“伴随变化”和“因果链条”的标准操作。

Fig. 2：EGFR signaling promotes RRM2 transactivation through MYBL2 in PC-9 and HCC827 cells. A, ChIP fol- lowed by qPCR (ChIP–qPCR) was performed using an anti-RNAPII (8WG16) antibody to evaluate the recruitment of RNAPII to the RRM2 promoter, with or without Osi treatment. Relative enrichment was normalized to the ACTB promoter. B, ChIP–qPCR using HA-tagged MYBL2-overexpressing cell lines was conducted to assess MYBL2 binding to the RRM2 promoter. Promoter occupancy is shown relative to input. Data are presented as mean ± SEM (n ¼ 3). , P < 0.001. C, RRM2 mRNA expression was quantified using RT-qPCR in PC-9 and HCC827 cells following EGFR knockdown (KD) using siRNA. Transcript levels were normalized to GAPDH. D, The impact of EGFR KD on MYBL2 re- cruitment to the RRM2 promoter was evaluated by ChIP–qPCR in HA- MYBL2–expressing cells transfected with control or EGFR siRNA. Pro- moter enrichment was normalized to input. Data are shown as mean ± SEM (n ¼ 3), and P values are indi- cated. All data are representative of at least three independent experi- ments. NC, negative control.

Fig. 2. EGFR signaling promotes RRM2 transactivation through MYBL2 in PC-9 and HCC827 cells. A, ChIP fol- lowed by qPCR (ChIP–qPCR) was performed using an anti-RNAPII (8WG16) antibody to evaluate the recruitment of RNAPII to the RRM2 promoter, with or without Osi treatment. Relative enrichment was normalized to the ACTB promoter. B, ChIP–qPCR using HA-tagged MYBL2-overexpressing cell lines was conducted to assess MYBL2 binding to the RRM2 promoter. Promoter occupancy is shown relative to input. Data are presented as mean ± SEM (n ¼ 3). , P < 0.001. C, RRM2 mRNA expression was quantified using RT-qPCR in PC-9 and HCC827 cells following EGFR knockdown (KD) using siRNA. Transcript levels were normalized to GAPDH. D, The impact of EGFR KD on MYBL2 re- cruitment to the RRM2 promoter was evaluated by ChIP–qPCR in HA- MYBL2–expressing cells transfected with control or EGFR siRNA. Pro- moter enrichment was normalized to input. Data are shown as mean ± SEM (n ¼ 3), and P values are indi- cated. All data are representative of at least three independent experi- ments. NC, negative control.（图注取自PDF文本层，来源：Cancer Research, 2026）

第三步：RRM2被压下去了，细胞怎么自救？

既然RRM2被抑制导致嘧啶dNTP不够，DNA复制肯定会出问题。他们用DNA纤维实验直接看复制叉推进速度：奥希替尼处理后的CldU/IdU比值明显变小，说明复制叉“卡顿”了。同时彗星实验显示DNA双链断裂显著增加——复制压力确实转化成了基因组损伤。

但有趣的是，RRM2B在奥希替尼处理后逐步上调，在48小时达到峰值。那RRM2B上调是干什么的？他们把RRM2B敲低后发现：奥希替尼引起的嘧啶dNTP下降更加严重，而且恢复期完全消失。彗星实验也显示DNA损伤进一步加剧。

@方法论点评：这里的关键是时间窗口的设计——RRM2下降是快速的（24小时内），RRM2B上升是缓慢累积的。这种时间差本身就说明RRM2B是“代偿性”诱导而非同步调控。敲除实验证明它确实起到了恢复dNTP池、缓解复制压力的作用。

所以结论很清楚了：奥希替尼压制RRM2 → dNTP失衡 → 复制压力 → 细胞通过诱导RRM2B来“补位”。那下一步就是：RRM2B是怎么被诱导的？

Fig. 3：Osi disrupts DNA replication fork progression and induces double- strand DNA breaks in EGFR-mutant NSCLC cells. A, Representative DNA fiber images from the indicated cell lines under different treatment con- ditions. Cells were labeled sequen- tially with IdU (red) for 1 hour without treatment, followed by CldU (green) in the presence of Osi, dNTP supple- mentation, or their combination. DNA fibers were then isolated and spread to analyze replication dynamics. B, Quantification of replication fork progression, shown as the ratio of CldU to IdU track lengths for indi- vidual DNA fibers. C, Representative comet assay images showing DNA damage in HCC827 and PC-9 cells after a 24-hour treatment with DMSO (control), Osi (5 μmol/L), dNTPs (25 μmol/L), or the combination of Osi and dNTPs. D, Quantification of DNA damage, expressed as comet tail moment, under the indicated conditions. Data reflect the extent of double-strand DNA breaks in re- sponse to treatment.

Fig. 3. Osi disrupts DNA replication fork progression and induces double- strand DNA breaks in EGFR-mutant NSCLC cells. A, Representative DNA fiber images from the indicated cell lines under different treatment con- ditions. Cells were labeled sequen- tially with IdU (red) for 1 hour without treatment, followed by CldU (green) in the presence of Osi, dNTP supple- mentation, or their combination. DNA fibers were then isolated and spread to analyze replication dynamics. B, Quantification of replication fork progression, shown as the ratio of CldU to IdU track lengths for indi- vidual DNA fibers. C, Representative comet assay images showing DNA damage in HCC827 and PC-9 cells after a 24-hour treatment with DMSO (control), Osi (5 μmol/L), dNTPs (25 μmol/L), or the combination of Osi and dNTPs. D, Quantification of DNA damage, expressed as comet tail moment, under the indicated conditions. Data reflect the extent of double-strand DNA breaks in re- sponse to treatment.（图注取自PDF文本层，来源：Cancer Research, 2026）

Fig. 4：

Fig. 4. （图注取自PDF文本层，来源：Cancer Research, 2026）

第四步：TNNT3是RRM2B的“非典型”转录激活因子

PC-9和HCC827都是p53突变的细胞，而RRM2B经典上是p53的靶基因——p53失灵了，RRM2B靠什么被诱导？

他们注意到之前有报道称TNNT3能在骨骼肌中调控RRM2B转录，与p53通路平行。于是他们检测了TNNT3在奥希替尼处理后的定位变化：TNNT3在24小时后明显向染色质结合组分富集。敲低TNNT3后，RRM2B的蛋白和mRNA诱导都显著被削弱。

克隆形成实验进一步证明：RRM2B敲低让细胞对奥希替尼更敏感，而过表达RRM2B则增强耐受。这说明TNNT3-RRM2B这条非经典通路在p53缺陷的背景下充当了“救命稻草”。

@方法论点评：这是在“已知通路失灵”的背景下寻找替代通路的经典策略——先排除经典解释（p53突变），再基于文献线索提出替代假设（TNNT3），最后用敲低和过表达做功能验证。每一步都有明确的排除-假设-验证逻辑。

Fig. 5：Transactivation of RRM2B by TNNT3 following Osi treatment is important for the acquisition of Osi resis- tance. A, PC-9 and HCC827 cells were treated with 5 nmol/L of Osi for the indicated time points, and chromatin-bound (CB) fractions were prepared. TNNT3 protein levels were analyzed by Western blot- ting; ACTB and histone H3 were used as loading con- trols. Data shown are representative of three independent experiments. B, PC-9 and HCC827 cells were transfected with siRNA control and TNNT3 for 48 hours, followed by 5 nmol/L of Osi treatment for 24 hours. Protein expression of TNNT3 and RRM2B was assessed by WB, with GAPDH as a loading control. Re- sults shown are representative of three independent experiments. C, PC-9 and HCC827 cells were transfected with control or TNNT3 siRNA 24 hours prior to Osi treatment. Protein levels of TNNT3 and RRM2B were analyzed by Western blotting, with ACTB as a loading control. Results are representative of three independent experiments. D, Representative images from colony formation assays in PC-9 and HCC827 cells transfected with control siRNA, RRM2B siRNA, or FLAG-tagged RRM2B and treated with varying concentrations of Osi. E, Quantification of colony density in treated cells from D. Data reflect the impact of RRM2B modulation on cellular resistance to Osi. O/E, overexpression; NC, neg- ative control; WCE, whole cell extraction.

Fig. 5. Transactivation of RRM2B by TNNT3 following Osi treatment is important for the acquisition of Osi resis- tance. A, PC-9 and HCC827 cells were treated with 5 nmol/L of Osi for the indicated time points, and chromatin-bound (CB) fractions were prepared. TNNT3 protein levels were analyzed by Western blot- ting; ACTB and histone H3 were used as loading con- trols. Data shown are representative of three independent experiments. B, PC-9 and HCC827 cells were transfected with siRNA control and TNNT3 for 48 hours, followed by 5 nmol/L of Osi treatment for 24 hours. Protein expression of TNNT3 and RRM2B was assessed by WB, with GAPDH as a loading control. Re- sults shown are representative of three independent experiments. C, PC-9 and HCC827 cells were transfected with control or TNNT3 siRNA 24 hours prior to Osi treatment. Protein levels of TNNT3 and RRM2B were analyzed by Western blotting, with ACTB as a loading control. Results are representative of three independent experiments. D, Representative images from colony formation assays in PC-9 and HCC827 cells transfected with control siRNA, RRM2B siRNA, or FLAG-tagged RRM2B and treated with varying concentrations of Osi. E, Quantification of colony density in treated cells from D. Data reflect the impact of RRM2B modulation on cellular resistance to Osi. O/E, overexpression; NC, neg- ative control; WCE, whole cell extraction.（图注取自PDF文本层，来源：Cancer Research, 2026）

第五步：CHK2是这条代偿通路的上游开关

那TNNT3又是怎么被激活和入核的？他们观察到奥希替尼处理下CHK1信号被持续抑制（蛋白水平下降），而CHK2则出现短暂的磷酸化激活。两种检查点激酶表现出完全相反的动态。

用CHK2抑制剂PV1019处理，TNNT3的染色质结合减少，RRM2B诱导也被阻断，POLD1和POLH在染色质组分中的募集显著下降——说明CHK2负责把TNNT3“送进核内启动转录”。

用CHK1/2双抑制剂LY2606368也能得到类似效果。而且他们发现TNNT3的降解与蛋白酶体有关（MG132能部分挽救），但具体E3泛素连接酶还没找到。

@方法论点评：这里用“功能阻断”实验证明上游激酶的作用——不是只靠相关性（磷酸化时间点吻合），而是直接抑制CHK2看下游变化。而且注意到CHK1抑制是持续的、CHK2激活是瞬时的，这种动态差异本身就有生物学意义。

Fig. 6：Activation of the CHK2 pathway following Osi treat- ment is important for maintaining resistance to Osi. A, A549, PC-9, and HCC827 cells were treated with 5 nmol/L of Osi. Protein levels of phosphorylated CHK1 (p-CHK1), phosphorylated CHK2 (p-CHK2), total CHK1, and CHK2 were analyzed by Western blotting. GAPDH served as a loading control. Data are representative of three independent experiments. B, Cells were treated as in A, with MG132 added 2 hours before harvest. Protein levels of p-CHK1, p-CHK2, CHK1, and CHK2 were assessed by Western blotting. ACTB was used as a loading control. Data represent three independent ex- periments. C, Proliferation assays in HCC827 and PC-9 cells treated with increasing concentrations of Osi alone or in combination with PV1019 (CHK2 inhibitor, concentration unspecified). D, PC-9 cells were treated with DMSO, 5 nmol/L of Osi, 10 μmol/L of PV1019, or the combination for the indicated times. Nuclear fractions were analyzed by Western blotting for RRM1, RRM2, RRM2B, POLD1, POLH, and TNNT3. ACTB and histone H3 were used as loading controls. E, PC-9 cells were treated with DMSO, 5 nmol/L of Osi, 10 nmol/L of LY2606368 (CHK1/ CHK2 inhibitor), or the combination for the indicated times. Nuclear extracts were analyzed as in D. Data are representative of three independent experiments. CB, chromatin bound; WCE, whole cell extraction.

Fig. 6. Activation of the CHK2 pathway following Osi treat- ment is important for maintaining resistance to Osi. A, A549, PC-9, and HCC827 cells were treated with 5 nmol/L of Osi. Protein levels of phosphorylated CHK1 (p-CHK1), phosphorylated CHK2 (p-CHK2), total CHK1, and CHK2 were analyzed by Western blotting. GAPDH served as a loading control. Data are representative of three independent experiments. B, Cells were treated as in A, with MG132 added 2 hours before harvest. Protein levels of p-CHK1, p-CHK2, CHK1, and CHK2 were assessed by Western blotting. ACTB was used as a loading control. Data represent three independent ex- periments. C, Proliferation assays in HCC827 and PC-9 cells treated with increasing concentrations of Osi alone or in combination with PV1019 (CHK2 inhibitor, concentration unspecified). D, PC-9 cells were treated with DMSO, 5 nmol/L of Osi, 10 μmol/L of PV1019, or the combination for the indicated times. Nuclear fractions were analyzed by Western blotting for RRM1, RRM2, RRM2B, POLD1, POLH, and TNNT3. ACTB and histone H3 were used as loading controls. E, PC-9 cells were treated with DMSO, 5 nmol/L of Osi, 10 nmol/L of LY2606368 (CHK1/ CHK2 inhibitor), or the combination for the indicated times. Nuclear extracts were analyzed as in D. Data are representative of three independent experiments. CB, chromatin bound; WCE, whole cell extraction.（图注取自PDF文本层，来源：Cancer Research, 2026）

第六步：打断代偿通路，能延迟耐药吗？

这是最关键的治疗转化验证。他们在体外用逐步递增奥希替尼浓度的方法模拟耐药形成过程——单药组大约120-200天到达耐药；而联合PV1019或LY2606368组，耐药出现时间明显延后。

在HCC827异种移植模型里，奥希替尼单药组中位TTE是55天；加上高剂量LY2606368后，中位TTE显著延长到65天以上（log-rank P=0.0284）。联合治疗组在整个观察期内肿瘤都未达终点体积。

他们还在耐药肿瘤里测了基因表达：RRM2B、RRM2、MYBL2都反弹了——说明耐药建立后，原本被压制的通路又重新激活了。

@方法论点评：体内实验最大的价值是“生理环境下的验证”，特别是药物联合的时间窗和剂量关系。体外延迟耐药可以证明“可能性”，体内证明“可行性”——两者缺一不可。此外，耐药后重新检测分子标志物，说明耐药不是“绕开”了这条通路，而是“重新启用了”它。

Fig. 7：CHK1/2 inhibition delays the acquisition of resistance to Osi in PC-9 and HCC827 cells, and its combination with Osi enhances the antitumor effect in vivo. A, Workflow for establishing Osi resistance in PC-9 and HCC827 cells. Cells were seeded at low density and treated with Osi alone or together with CHK inhibitors (PV or LY). Drug concentrations were increased stepwise as cells resumed proliferation, and IC50 values were periodically measured to plot acquired resistance– time curves. B, Time-dependent acquisition of Osi resistance in PC-9 and HCC827 cells treated with Osi alone or in combination with CHK inhibitors (Osi + PV or Osi + LY), as assessed by Osi IC50 measurements. C, Tumor volumes (mm3) were measured longitudinally in mice treated with vehicle control, Osi (1.67 mg/kg), LY2606368 (low dose 3.33 mg/kg or high dose 10 mg/kg), or combinations of Osi with LY2606368 (low or high dose). Data are presented as mean ± SEM (n ¼ 3), and P values are indicated. All results are representative of at least three independent experiments. The red horizontal line indicates the predefined tumor volume endpoint (1,000 mm3). TTE was analyzed using Kaplan–Meier methods and compared between groups using the log-rank (Mantel–Cox) test. The median TTE values are indicated for Osi (55 days), Osi + LY2606368 (low dose; 65 days, P ¼ 0.3555), and Osi + LY2606368 (high dose; ≥65 days, P ¼ 0.0284), with comparisons made relative to Osi monotherapy. D, Relative mRNA expression levels of RRM2B, RRM2, MYBL2, TNNT3, and CHK1 in tumor tissues following treatment with DMSO or Osi, as measured by RT-qPCR.

Fig. 7. CHK1/2 inhibition delays the acquisition of resistance to Osi in PC-9 and HCC827 cells, and its combination with Osi enhances the antitumor effect in vivo. A, Workflow for establishing Osi resistance in PC-9 and HCC827 cells. Cells were seeded at low density and treated with Osi alone or together with CHK inhibitors (PV or LY). Drug concentrations were increased stepwise as cells resumed proliferation, and IC50 values were periodically measured to plot acquired resistance– time curves. B, Time-dependent acquisition of Osi resistance in PC-9 and HCC827 cells treated with Osi alone or in combination with CHK inhibitors (Osi + PV or Osi + LY), as assessed by Osi IC50 measurements. C, Tumor volumes (mm3) were measured longitudinally in mice treated with vehicle control, Osi (1.67 mg/kg), LY2606368 (low dose 3.33 mg/kg or high dose 10 mg/kg), or combinations of Osi with LY2606368 (low or high dose). Data are presented as mean ± SEM (n ¼ 3), and P values are indicated. All results are representative of at least three independent experiments. The red horizontal line indicates the predefined tumor volume endpoint (1,000 mm3). TTE was analyzed using Kaplan–Meier methods and compared between groups using the log-rank (Mantel–Cox) test. The median TTE values are indicated for Osi (55 days), Osi + LY2606368 (low dose; 65 days, P ¼ 0.3555), and Osi + LY2606368 (high dose; ≥65 days, P ¼ 0.0284), with comparisons made relative to Osi monotherapy. D, Relative mRNA expression levels of RRM2B, RRM2, MYBL2, TNNT3, and CHK1 in tumor tissues following treatment with DMSO or Osi, as measured by RT-qPCR.（图注取自PDF文本层，来源：Cancer Research, 2026）

核心结论

EGFR-MYBL2-RRM2和CHK2-TNNT3-RRM2B构成一个双向dNTP调控网络：奥希替尼切断第一条臂（抑制RRM2），细胞立刻启动第二条臂（诱导RRM2B）来代偿。两条臂都指向同一个目标——维持dNTP池稳定，保障DNA复制和损伤修复。CHK1/2抑制剂能有效拆除第二条臂，使细胞无法完成代谢代偿，从而巩固奥希替尼的杀伤效果并延迟耐药。

补充实验还提示：长期耐药后，细胞可能从“从头合成”转向“补救途径”（TK1和DCK上调）。RRM2B的诱导更像一个“过渡性桥梁”，帮细胞撑过药物打击的急性期，为后续更稳定的耐药状态争取时间。

对耐药/DTP/PGCC 的启示

DTP的形成或许依赖“代谢代偿”的时间窗口：奥希替尼处理早期，RRM2被压、RRM2B还未充分诱导的间隙，是最脆弱的阶段。CHK1/2抑制剂把这个窗口“拉长”了，阻止细胞建立耐受。这提示DTP的治疗干预应该聚焦在“代谢适应期”而非耐药已经建立之后。 RRM2B是p53突变肿瘤的特异性“可靶点”：p53在NSCLC中突变率极高，经典DNA损伤应答通路本身就失灵了，细胞只能依赖TNNT3这类非经典通路来维持基因组稳定性。这既是脆弱点，也是治疗窗口——对正常组织影响可能更小。 代谢表型会随耐药演化而漂移：早期依赖RRM2B补救，后期转向TK1/DCK补救通路。单一时间点的代谢标志物可能不足以预测耐药状态，需要在治疗过程中动态监测dNTP代谢网络的重塑方向。这也提醒我们，联合治疗的时间窗可能很窄——太早可能毒性大，太晚细胞已经“换了燃料”。

局限

文中E3泛素连接酶的具体身份未鉴定出来（TNNT3的降解机制还不完全清楚）。 RRM2B敲低的长期克隆显示mtDNA/nDNA比值升高，文中解释为“线粒体功能克隆筛选”，但具体机制没有深挖。 体内实验用的是CDX模型，免疫系统的角色没有涉及；肿瘤微环境对dNTP代谢的调控有待后续研究。 细胞系仅限于PC-9和HCC827，虽然补充了SW48（结直肠癌EGFR突变），但更多EGFR突变亚型（如L858R、T790M、C797S）覆盖不足。

来源

期刊：Cancer Research，2026。DOI: 10.1158/0008-5472.can-25-3237